Vortrag am FONDS professionell KONGRESSCORE Neu erfunden: Erwarten Sie mehr von kostengünstigen Aktien-ETFs
Investoren hinterfragen zunehmend die Ineffizienz von Massentrades. Core-Aktien-ETFs müssen zu Gunsten des Anlegers neu definiert werden. Klicken Sie hier, um mehr zu erfahren.
AnzeigeUBS(Lux)Equity Fund Biotech (USD) P acc
| MVD-Fonds Rating | EDA |
|---|---|
  | 71 |
ISIN: LU0069152568 | WKN: 986327
KAG: UBS AG Lux
NAV: 592,40 USD am 17.01.2019
Portfolio
Watchlist
Kursalarm
Kennzahlen UBS(Lux)Equity Fund Biotech (USD) P acc
| 1M | 6M | 1J | 3J | 5J | 10J | Beginn | |
| Performance | +8,83% | -8,23% | -3,06% | +25,58% | +29,64% | +314,33% | +485,33% |
| Volatilität | +36,41% | +27,00% | +25,70% | +23,70% | +26,14% | +24,67% | +28,01% |
| Sharpe Ratio | +4,95 | -0,57 | -0,11 | +0,35 | +0,22 | +0,63 | +0,31 |
| Bester Monat | - | +12,71% | +12,71% | +12,71% | +14,26% | +15,66% | +34,90% |
| Schl. Monat | - | -13,55% | -13,55% | -21,18% | -21,18% | -21,18% | -28,60% |
| Max. Verlust | -10,27% | -25,18% | -25,72% | -25,72% | -40,97% | -40,97% | -75,23% |
Monatsperformance UBS(Lux)Equity Fund Biotech (USD) P acc
| 2019 | 2018 | 2017 | 2016 | 2015 | |
| Januar | +12,71% | +5,71% | +6,27% | -21,18% | +7,11% |
| Februar | - | -5,26% | +8,25% | -4,52% | +4,81% |
| März | - | -3,10% | -0,69% | +4,31% | +1,44% |
| April | - | -2,78% | +2,18% | +5,16% | -5,66% |
| Mai | - | +4,87% | -4,40% | +3,27% | +9,36% |
| Juni | - | +2,42% | +9,86% | -7,16% | -0,51% |
| Juli | - | +2,97% | +3,77% | +12,18% | +1,80% |
| August | - | +4,44% | +4,70% | -2,49% | -11,57% |
| September | - | -2,08% | -0,21% | +3,60% | -11,56% |
| Oktober | - | -13,55% | -6,89% | -12,31% | +8,37% |
| November | - | +5,61% | -0,31% | +8,49% | +2,47% |
| Dezember | - | -9,74% | +1,68% | -2,83% | -1,71% |
| Gesamt | +12,71% | -12,06% | +25,45% | -17,09% | +1,58% |
